Abstract Body

Background

The global burden of viral hepatitis B (HBV) is substantial, and monitoring progress across the care cascade is essential to plan elimination strategies. In Sub-Saharan Africa, data on the HBV care cascade are limited. We examined the HBV care cascade in Rwanda from 2016 to 2023.

Methods

In this population-based retrospective cohort study, we used routinely collected data from the District Health Information System 2, which included over 4.6 million people screened for HBV from January 2016 to June 2023. During this period, individuals were included if they were >2 years old. The HBV care cascade was analyzed across six stages: (1) lifetime prevalence, (2) diagnosis, (3) enrolled in care, (4) eligible to treatment, (5) treatment initiation, and (6) treatment continuation. Infection was defined as presence of at least one reactive hepatitis B surface antigen (HBsAg). Lifetime prevalence was estimated as the sum of diagnosed and estimated undiagnosed cases. Hierarchical logistic regression was used to identify progression-related factors through the different cascade stages. 

Results

Among 4,604,468 individuals screened, 57,520 tested positive for HBsAg, of which 52,827 (91.8%) had HBV mono-infection and 4,693 (8.2%) were co-infected with HIV. Of those diagnosed, 21,247 (37.0%) were enrolled in care, and 6,429 (30.3%) of the enrolled individuals were eligible for treatment. Of those eligible, 4,893 (76.1%) initiated treatment, and 4,839 (98.9%) were retained on treatment at one-year post-initiation. Individuals aged 35–54 were more likely to engage in care (adjusted odds ratio [aOR], 1.19; 95% CI: 1.12–1.27), initiate treatment (aOR, 1.45; 95% CI: 1.14–1.86), and be retained on treatment (aOR, 2.88; 95% CI: 1.09–7.63) compared to those under 35. Individuals living 30 minutes to 1 hour from a health facility were less likely to engage in care or remain on treatment compared to those living closer to a facility.

Conclusions

Overall, engagement with care was low, which highlights the need to strengthen awareness among general population regarding HBV prevention and control. Younger individuals and those living farther from health facilities are less likely to engage in care and remain on treatment. Strengthening lower-level health facilities by expanding the number of trained healthcare providers and improving infrastructure is critical to enhance HBV prevention and treatment at the community level.

Table or Figure